Evaluation of Alternative Splicing Regulators as Targets for Selective Therapy of Triple-Negative (Basal) Breast Carcinoma
Abstract
We failed to generate an antibody specific to SRSF12 (Task 1). This is the second attempt to generate such antibody and we have exhausted the suitable antigenic regions. The SRSF12 antibody is a reagent that is critical for the work related to SRSF12 under Tasks 1, 2, 4, 5, and 6. Under Task 3, we completed the backcrossing the of KHDRBS3 and SRPK knockout alleles into the SV129 genetic background and we are generating the experimental animals that combine the transgene with the knockout alleles. Under Task 4, we analyzed the expression of KHDRBS3 in a breast cancer tissue array, tissue samples from the WVU pathology core and patient derived tumor xenografts. The analysis confirms that KHDRBS3 is associated with triple negative breast cancer. Under Task 5, we examined the roles of the PI3 kinase pathway, and cMyc on the expression of KHDRBS3. We concluded that KHDRBS3 expression is not controlled by these factors. Tasks 1, 2, and 6 are now complete. The work under these tasks related to SRPK1 and KHDRBS3 is complete, and the work related to SRSF12 is no longer feasible due to the lack of a specific antibody.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1094559
Entities
People
- Peter Stoilov
Organizations
- West Virginia University